ArticleAccounts of chemical research2015
Academia-industry symbiosis in organic chemistry.
Article in Accounts of chemical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Site-Divergent Oxidations within Venerable Macrolide Antibiotic Scaffolds Unveil Compounds with Broad Spectrum and Anti-MRSA Activities.ACS central science · 2026Article
- Accelerating compound synthesis in drug discovery: the role of digitalisation and automation.RSC medicinal chemistry · 2025Article
- Evolving Landscape: Accounts of Academic-Industrial Collaborations in Chemistry Technology.ACS medicinal chemistry letters · 2025Review
- Connecting chemical worlds for a sustainable future.Chemical science · 2024Review
- Alkyl sulfinates as cross-coupling partners for programmable and stereospecific installation of C(spNature chemistry · 2023Article
- C-H functionalisation tolerant to polar groups could transform fragment-based drug discovery (FBDD).Chemical science · 2021Article
- Practical and Regioselective Synthesis of C-4-Alkylated Pyridines.Journal of the American Chemical Society · 2021Article
- Emergent synthetic methods for the modular advancement of spChemical science · 2021Review
- Quick Building Blocks (QBB): An Innovative and Efficient Business Model To Speed Medicinal Chemistry Analog Synthesis.ACS medicinal chemistry letters · 2019Article
- A Holistic Approach to Streamlining Pharmaceutical Processes: A Conversation.Organic process research & development · 2019Review
- Organic synthesis provides opportunities to transform drug discovery.Nature chemistry · 2018Review
- An Enlightening Reactor.ACS central science · 2017Article
- Peptide Macrocyclization Inspired by Non-Ribosomal Imine Natural Products.Journal of the American Chemical Society · 2017Article
- Strain-Release Heteroatom Functionalization: Development, Scope, and Stereospecificity.Journal of the American Chemical Society · 2017Article
- Scalable Synthesis of (-)-Thapsigargin.ACS central science · 2017Article
- Evaluating New Chemistry to Drive Molecular Discovery: Fit for Purpose?Angewandte Chemie (International ed. in English) · 2016Review
- Radicals: Reactive Intermediates with Translational Potential.Journal of the American Chemical Society · 2016Review
- Enabling Technologies for the Future of Chemical Synthesis.ACS central science · 2016Review
- Antroquinonol A: Scalable Synthesis and Preclinical Biology of a Phase 2 Drug Candidate.ACS central science · 2016Article
- Organic chemistry. Strain-release amination.Science (New York, N.Y.) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Collaboration between academia and industry is a growing phenomenon within the chemistry community. These sectors have long held strong ties since academia traditionally trains the future scientists of the corporate world, but the recent drastic decrease of public funding is motivating the academic world to seek more private grants. This concept of industrial "sponsoring" is not new, and in the past, some companies granted substantial amounts of money per annum to various academic institutions in exchange for prime access to all their scientific discoveries and inventions. However, academic and industrial interests were not always aligned, and therefore the investment has become increasingly difficult to justify from industry's point of view. With fluctuating macroeconomic factors, this type of unrestricted grant has become more rare and has been largely replaced by smaller and more focused partnerships. In our view, forging a partnership with industry can be a golden opportunity for both parties and can represent a true symbiosis. This type of project-specific collaboration is engendered by industry's desire to access very specific academic expertise that is required for the development of new technologies at the forefront of science. Since financial pressures do not allow companies to spend the time to acquire this expertise and even less to explore fundamental research, partnering with an academic laboratory whose research is related to the problem gives them a viable alternative. From an academic standpoint, it represents the perfect occasion to apply "pure science" research concepts to solve problems that benefit humanity. Moreover, it offers a unique opportunity for students to face challenges from the "real world" at an early stage of their career. Although not every problem in industry can be solved by research developments in academia, we argue that there is significant scientific overlap between these two seemingly disparate groups, thereby presenting an opportunity for a symbiosis. This type of partnership is challenging but can be a win-win situation if both parties agree on some general guidelines, including clearly defined goals and deliverables, biweekly meetings to track research progress, and quarterly or annual meetings to recognize overarching, common objectives. This Account summarizes our personal experience concerning collaborations with various industrial groups and the way it impacted the research programs for both sides in a symbiotic fashion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.